Multiple sclerosis

Multiple sclerosis

A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Molecular Stethoscope, Inc.
December 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of a human proof-of-concept study for...
November 10, 2020
BioSpace
FibroGenesis Announces the Filing of its 250th Patent for Fibroblast Cell Therapy Platform - read this article along with other careers information, tips and advice on BioSpace
FibroGenesis
November 10, 2020
www.prnewswire.com:443
/PRNewswire/ -- FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal...
September 10, 2019
WebWire
, , , , • Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent ® (siponimod) and Gilenya ® (fingolimod) , , , , • Results from head-to-head Phase III ASCLEPIOS studies evaluating efficacy and safety of ofatumumab, an investigational B-cell therapy that potentially can be administered subcutaneously at home by patients with relapsing multiple s...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.